http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008036717-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b8be2ef48c55755089dddb551c4d1923 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_addfe653fadb23d7b6f74ea5fabcff08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1732 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 |
| filingDate | 2007-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_112c999c0239c6956145759ae994167d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1041ffff036c4385cb6c4e403a45cca5 |
| publicationDate | 2008-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2008036717-A2 |
| titleOfInvention | Use of soluble galectin-3 (gal-3) for cancer treatment |
| abstract | The present invention provides a method for preventing or treating cancer or tumorgenesis disorder comprising administering a prevention or treatment effective amount of a p53 mediated secretome component, such as Gal-3, to a patient in need thereof, thereby preventing or treating cancer or tumorgenesis disorders. Compositions and methods useful for modulating the secretome, including Gal-3, of a cell, comprising increasing extracellular levels of Gal-3, p53 expression, or expression of a downstream effector of p53, in the cell are also provided. Furthermore, methods for identifying tumor targets, diagonostic or prognostic indicators, and therapeutic strategies comprising determining extracellular levels of secreted proteins or secretomes, including Gal-3 are also provided. The present invention provides a novel tumor suppressive mechanism of p53 involving paracrine induction of apoptosis through extracellular Gal-3 levels. The invention also provides evidence that cancer cells are more susceptible to the treatment than normal cells, suggesting augmented expression of the receptor component to Gal3. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10260104-B2 |
| priorityDate | 2006-09-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 559.